Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells

Autores
Medina-Montano, Carolina; Rivero Berti, Ignacio; Gambaro, Rocío Celeste; Limeres, María José; Svensson, Malin; Padula, Gisel; Chain, Cecilia Yamil; Cisneros, José Sebastián; Castro, Guillermo Raúl; Grabbe, Stephan; Bros, Matthias; Gehring, Stephan; Islan, Germán Abel; Cacicedo, Maximiliano Luis
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Liver inflammation represents a major clinical problem in a wide range of pathologies. Among the strategies to prevent liver failure, dexamethasone (DXM) has been widely used to suppress inflammatory responses. The use of nanocarriers for encapsulation and sustained release of glucocorticoids to liver cells could provide a solution to prevent severe side effects associated with systemic delivery as the conventional treatment regime. Here we describe a nanostructured lipid carrier developed to efficiently encapsulate and release DXM. This nano-formulation proved to be stable over time, did not interact in vitro with plasma opsonins, and was well tolerated by primary non-parenchymal liver cells (NPCs). Released DXM preserved its pharmacological activity, as evidenced by inducing robust anti-inflammatory responses in NPCs. Taken together, nanostructured lipid carriers may constitute a reliable platform for the delivery of DXM to treat pathologies associated with chronic liver inflammation.
Centro de Investigación y Desarrollo en Fermentaciones Industriales
Instituto de Genética Veterinaria
Instituto de Investigaciones Fisicoquímicas Teóricas y Aplicadas
Materia
Ciencias Exactas
Farmacia
glucocorticoids
lipid nanoparticles
liver inflammation
liver immunology
autoimmune hepatitis
dexamethasone
drug-controlled release
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/154307
Acceder
id SEDICI_7a1e1dcfd5238790d5d1dcc30b80f1b8
oai_identifier_str oai:sedici.unlp.edu.ar:10915/154307
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver CellsMedina-Montano, CarolinaRivero Berti, IgnacioGambaro, Rocío CelesteLimeres, María JoséSvensson, MalinPadula, GiselChain, Cecilia YamilCisneros, José SebastiánCastro, Guillermo RaúlGrabbe, StephanBros, MatthiasGehring, StephanIslan, Germán AbelCacicedo, Maximiliano LuisCiencias ExactasFarmaciaglucocorticoidslipid nanoparticlesliver inflammationliver immunologyautoimmune hepatitisdexamethasonedrug-controlled releaseLiver inflammation represents a major clinical problem in a wide range of pathologies. Among the strategies to prevent liver failure, dexamethasone (DXM) has been widely used to suppress inflammatory responses. The use of nanocarriers for encapsulation and sustained release of glucocorticoids to liver cells could provide a solution to prevent severe side effects associated with systemic delivery as the conventional treatment regime. Here we describe a nanostructured lipid carrier developed to efficiently encapsulate and release DXM. This nano-formulation proved to be stable over time, did not interact in vitro with plasma opsonins, and was well tolerated by primary non-parenchymal liver cells (NPCs). Released DXM preserved its pharmacological activity, as evidenced by inducing robust anti-inflammatory responses in NPCs. Taken together, nanostructured lipid carriers may constitute a reliable platform for the delivery of DXM to treat pathologies associated with chronic liver inflammation.Centro de Investigación y Desarrollo en Fermentaciones IndustrialesInstituto de Genética VeterinariaInstituto de Investigaciones Fisicoquímicas Teóricas y Aplicadas2022-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/154307enginfo:eu-repo/semantics/altIdentifier/issn/1999-4923info:eu-repo/semantics/altIdentifier/doi/10.3390/pharmaceutics14081611info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-10-15T11:31:45Zoai:sedici.unlp.edu.ar:10915/154307Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-10-15 11:31:45.544SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells
title Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells
spellingShingle Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells
Medina-Montano, Carolina
Ciencias Exactas
Farmacia
glucocorticoids
lipid nanoparticles
liver inflammation
liver immunology
autoimmune hepatitis
dexamethasone
drug-controlled release
title_short Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells
title_full Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells
title_fullStr Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells
title_full_unstemmed Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells
title_sort Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells
dc.creator.none.fl_str_mv Medina-Montano, Carolina
Rivero Berti, Ignacio
Gambaro, Rocío Celeste
Limeres, María José
Svensson, Malin
Padula, Gisel
Chain, Cecilia Yamil
Cisneros, José Sebastián
Castro, Guillermo Raúl
Grabbe, Stephan
Bros, Matthias
Gehring, Stephan
Islan, Germán Abel
Cacicedo, Maximiliano Luis
author Medina-Montano, Carolina
author_facet Medina-Montano, Carolina
Rivero Berti, Ignacio
Gambaro, Rocío Celeste
Limeres, María José
Svensson, Malin
Padula, Gisel
Chain, Cecilia Yamil
Cisneros, José Sebastián
Castro, Guillermo Raúl
Grabbe, Stephan
Bros, Matthias
Gehring, Stephan
Islan, Germán Abel
Cacicedo, Maximiliano Luis
author_role author
author2 Rivero Berti, Ignacio
Gambaro, Rocío Celeste
Limeres, María José
Svensson, Malin
Padula, Gisel
Chain, Cecilia Yamil
Cisneros, José Sebastián
Castro, Guillermo Raúl
Grabbe, Stephan
Bros, Matthias
Gehring, Stephan
Islan, Germán Abel
Cacicedo, Maximiliano Luis
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Ciencias Exactas
Farmacia
glucocorticoids
lipid nanoparticles
liver inflammation
liver immunology
autoimmune hepatitis
dexamethasone
drug-controlled release
topic Ciencias Exactas
Farmacia
glucocorticoids
lipid nanoparticles
liver inflammation
liver immunology
autoimmune hepatitis
dexamethasone
drug-controlled release
dc.description.none.fl_txt_mv Liver inflammation represents a major clinical problem in a wide range of pathologies. Among the strategies to prevent liver failure, dexamethasone (DXM) has been widely used to suppress inflammatory responses. The use of nanocarriers for encapsulation and sustained release of glucocorticoids to liver cells could provide a solution to prevent severe side effects associated with systemic delivery as the conventional treatment regime. Here we describe a nanostructured lipid carrier developed to efficiently encapsulate and release DXM. This nano-formulation proved to be stable over time, did not interact in vitro with plasma opsonins, and was well tolerated by primary non-parenchymal liver cells (NPCs). Released DXM preserved its pharmacological activity, as evidenced by inducing robust anti-inflammatory responses in NPCs. Taken together, nanostructured lipid carriers may constitute a reliable platform for the delivery of DXM to treat pathologies associated with chronic liver inflammation.
Centro de Investigación y Desarrollo en Fermentaciones Industriales
Instituto de Genética Veterinaria
Instituto de Investigaciones Fisicoquímicas Teóricas y Aplicadas
description Liver inflammation represents a major clinical problem in a wide range of pathologies. Among the strategies to prevent liver failure, dexamethasone (DXM) has been widely used to suppress inflammatory responses. The use of nanocarriers for encapsulation and sustained release of glucocorticoids to liver cells could provide a solution to prevent severe side effects associated with systemic delivery as the conventional treatment regime. Here we describe a nanostructured lipid carrier developed to efficiently encapsulate and release DXM. This nano-formulation proved to be stable over time, did not interact in vitro with plasma opsonins, and was well tolerated by primary non-parenchymal liver cells (NPCs). Released DXM preserved its pharmacological activity, as evidenced by inducing robust anti-inflammatory responses in NPCs. Taken together, nanostructured lipid carriers may constitute a reliable platform for the delivery of DXM to treat pathologies associated with chronic liver inflammation.
publishDate 2022
dc.date.none.fl_str_mv 2022-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/154307
url http://sedici.unlp.edu.ar/handle/10915/154307
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/1999-4923
info:eu-repo/semantics/altIdentifier/doi/10.3390/pharmaceutics14081611
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1846064352845627392
score 13.22299

Publicaciones similares